Home » Stocks » RTRX

Retrophin, Inc. (RTRX)

Nov 19, 2020 - RTRX merged into TVTX
Stock Price: $24.25 USD 0.00 (0.00%)
Updated Nov 18, 2021 4:00 PM EST
Market Cap 1.24B
Revenue (ttm) 194.03M
Net Income (ttm) -78.07M
Shares Out 50.93M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Nov 18, 2021
Last Price $24.25
Previous Close $24.25
Change ($) 0.00
Change (%) 0.00%
Day's Open 24.57
Day's Range 24.01 - 24.74
Day's Volume 378,991
52-Week Range 8.98 - 24.96

News

Hide News
GlobeNewsWire - 2 months ago

Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in Novem...

Seeking Alpha - 2 months ago

Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Retrophin (RTRX) delivered earnings and revenue surprises of 25.42% and 6.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21

Zacks Investment Research - 2 months ago

Retrophin (RTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of...

GlobeNewsWire - 3 months ago

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement eq...

GlobeNewsWire - 3 months ago

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with foc...

GlobeNewsWire - 3 months ago

Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021

Seeking Alpha - 5 months ago

Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021

Zacks Investment Research - 5 months ago

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of...

Zacks Investment Research - 6 months ago

Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Suc...

GlobeNewsWire - 7 months ago

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price ...

GlobeNewsWire - 7 months ago

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, s...

Seeking Alpha - 8 months ago

Retrophin's (RTRX) CEO Eric Dube on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Retrophin (RTRX) delivered earnings and revenue surprises of 102.94% and 10.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 9 months ago

Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board

Zacks Investment Research - 10 months ago

Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.

GlobeNewsWire - 10 months ago

Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021

GlobeNewsWire - 10 months ago

SAN DIEGO, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORD...

Seeking Alpha - 10 months ago

Retrophin, Inc. (RTRX) CEO Eric Dube on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...

Zacks Investment Research - 1 year ago

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

Other stocks mentioned: ALKS, ATRA, AUTL, INVA
Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for November 7th

Other stocks mentioned: OLED, QRVO, TRNS
Zacks Investment Research - 1 year ago

The healthcare sector seems to be least affected by a protracted U.S.-China trade war.

Other stocks mentioned: DERM, LHCG, MRK
Seeking Alpha - 1 year ago

Retrophin, Inc. (RTRX) CEO Eric Dube on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Retrophin (RTRX) delivered earnings and revenue surprises of 22.73% and -2.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

Keeping up with the news from major medical meetings has become a requirement for healthcare investors.

Other stocks mentioned: APLS, RETA
Seeking Alpha - 1 year ago

Retrophin had two assets disappear from its pipeline this year.

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on qu...

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly ...

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare...

Zacks Investment Research - 1 year ago

Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.

The Motley Fool - 1 year ago

Find out how earnings and other factors hit these stocks.

Other stocks mentioned: SPLK, TLRY
The Motley Fool - 1 year ago

Retrophin's PKAN drug candidate missed the mark in a late-stage trial.

Investors Business Daily - 1 year ago

Retrophin stock collapsed to a three-year low Thursday after the biotech company's treatment for a rare nervous system disease failed in a Phase 3 test. The drug missed two key goals.

Benzinga - 1 year ago

Retrophin Inc (NASDAQ: RTRX) shares were plummeting Thursday following an adverse clinical readout from the company.

Market Watch - 1 year ago

Shares of Retrophin Inc. RTRX, +1.81% plunged 26% toward a 3 1/2-year low in premarket trading Thursday, after the biopharmaceutical company said a phase 3 trial of its treatment for pantothen...

GlobeNewsWire - 1 year ago

FORT Study did not achieve its primary or secondary endpoints

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Retrophin (RTRX) delivered earnings and revenue surprises of -48.72% and 4.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

About RTRX

Retrophin, a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC,... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Eric Dube
Employees
221
Stock Exchange
NASDAQ
Ticker Symbol
RTRX
Full Company Profile

Financial Performance

In 2019, Retrophin's revenue was $175.34 million, an increase of 6.75% compared to the previous year's $164.25 million. Losses were -$146.43 million, 42.6% more than in 2018.

Financial Statements